Medical Oncology

, Volume 27, Issue 3, pp 926–931 | Cite as

A case–control study of reproductive factors associated with subtypes of breast cancer in Northeast China

Original Paper

Abstract

Based on the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu (HER2), breast cancer is classified into several subtypes: luminal A (ER+ and/or PR+, HER2−), luminal B (ER+ and/or PR+, HER2+), HER2-overexpressing (ER−, PR−, and HER2+) and triple-negative (ER−, PR−, and HER2−). The aim of this case–control study is to determine reproductive factors associated with breast cancer subtypes in Chinese women. A total of 1,417 patients diagnosed with breast cancer in the First Affiliated Hospital, China Medical University, Shenyang, China between 2001 and 2009 and 1,587 matched controls without a prior breast cancer were enrolled. Personal interviews were conducted to obtain information on reproductive characteristics and clinical history. Relationships between the factors and the subtypes of breast cancer were examined using logistic regression to compute odds ratios (OR) and 95% confidence intervals (CI). Notably, luminal A (50.0%) was the most prevalent subtype relative to luminal B (15.10%), HER2-overexpressing (10.87%) and triple-negative (23.08%). Menarche at an early age was associated with a reduced risk of luminal A (OR, 2.35; 95% CI, 1.45–3.81). Breastfeeding protected parous women from any subtype of breast cancer. Postmenopause and spontaneous abortion were inversely associated with the risk of luminal tumors. By contrast, multiparity, family history of breast cancer and induced abortion increased the risk of breast cancer. Collectively, our findings suggest that reproductive factors such as age at menarche, parity, breastfeeding, menopausal status and abortion history have different effects on the subtypes of breast cancer in Chinese women.

Keywords

Breast cancer Luminal A Luminal B HER2-overexpressing Triple-negative Reproductive factor 

References

  1. 1.
    Perou C, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–52.CrossRefPubMedGoogle Scholar
  2. 2.
    Sorlie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Nielsen TO, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.CrossRefPubMedGoogle Scholar
  5. 5.
    Rakha EA, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42:3149–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Sørlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Shantakumar S, et al. Reproductive factors and breast cancer risk among older women. Breast Cancer Res Treat. 2007;102:365–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Kwan ML, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11:R31.CrossRefPubMedGoogle Scholar
  10. 10.
    Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008;113:1521–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17:2078–86.CrossRefPubMedGoogle Scholar
  12. 12.
    Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002;11:601–7.PubMedGoogle Scholar
  13. 13.
    Piper GL, Patel NA, Patel JA, Malay MB, Julian TB. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. Am Surg. 2004;70:1103–6.PubMedGoogle Scholar
  14. 14.
    Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Breast J. 2008;14:141–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Huang HJ, et al. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol. 2005;16:1755–61.CrossRefPubMedGoogle Scholar
  16. 16.
    Carey LA, et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst. 2005;97:1137–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Ihemelandu CU, et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol. 2007;14:2994–3003.CrossRefPubMedGoogle Scholar
  18. 18.
    Peeters PH, Verbeek AL, Krol A, Matthyssen MM, de Waard F. Age at menarche and breast cancer risk in nulliparous women. Breast Cancer Res Treat. 1995;33:55–61.CrossRefPubMedGoogle Scholar
  19. 19.
    Kotsopoulos J, et al. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005;16:667–74.CrossRefPubMedGoogle Scholar
  20. 20.
    Huo D, et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008;98:992–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Gajalakshmi V, et al. Breastfeeding and breast cancer risk in India: a multicenter case–control study. Int J Cancer. 2009;125:662–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Gao YT, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer. 2000;87:295–300.CrossRefPubMedGoogle Scholar
  23. 23.
    Shema L, Ore L, Ben-Shachar M, Haj M, Linn S. The association between breastfeeding and breast cancer occurrence among Israeli Jewish women: a case control study. J Cancer Res Clin Oncol. 2007;133:539–46.CrossRefPubMedGoogle Scholar
  24. 24.
    Lord SJ, et al. Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case–control study. Cancer Epidemiol Biomarkers Prev. 2008;17:1723–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Michels KB, Xue F, Colditz GA, Willett WC. Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med. 2007;167:814–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Clavel-Chapelon F, E3 N-EPIC Group. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer. 2002;86:723–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Burns PE, Lees AW, Hurlburt ME, May CL, Grace M. Reproductive events and family history as risk factors for breast cancer in northern Alberta. Can Med Assoc J. 1981;124:1451–7.PubMedGoogle Scholar
  28. 28.
    Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. For the Nurses’ Health Study Research Group. J Natl Cancer Inst. 1996;88:365–71.CrossRefPubMedGoogle Scholar
  29. 29.
    Olsson H, Bladström A. A cohort study of reproductive factors and family history of breast cancer in southern Sweden. Breast Cancer Res Treat. 2002;76:203–9.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  1. 1.Department of Oncology, The First Affiliated HospitalChina Medical UniversityShenyangChina

Personalised recommendations